We used a strategy based on transferrin-targeted self-assembling nanoparticles (SANPs) to deliver inhibitory RNA molecules targeting praja2 to the brain, thus demonstrating that praja2 is a relevant therapeutic target for GBM treatment and suggesting novel therapies based on RNA delivery. The gene discussed is PJA2; the disease is glioblastoma.